The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study
Background: The incidence of TB among Inuit is the highest in Canada. A significantly shorter latent TB infection (LTBI) treatment with rifapentine and isoniazid once weekly for 12 weeks (3HP) is now available in limited settings in Canada. Methods: A prospective open-label 2-year observational post...
Published in: | International Journal of Circumpolar Health |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Taylor & Francis Group
2020
|
Subjects: | |
Online Access: | https://doi.org/10.1080/22423982.2020.1758501 https://doaj.org/article/16425fe448d14bd6920642445f46808f |
id |
ftdoajarticles:oai:doaj.org/article:16425fe448d14bd6920642445f46808f |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:16425fe448d14bd6920642445f46808f 2023-05-15T14:57:54+02:00 The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study G. G. Alvarez D. Van Dyk R. Mallick S. Lesperance P. Demaio S. Finn S. Edmunds Potvin M. Patterson C. Pease K. Amaratunga C. Hui D.W. Cameron S. Mulpuru S.D. Aaron F. Momoli A. Zwerling 2020-01-01T00:00:00Z https://doi.org/10.1080/22423982.2020.1758501 https://doaj.org/article/16425fe448d14bd6920642445f46808f EN eng Taylor & Francis Group http://dx.doi.org/10.1080/22423982.2020.1758501 https://doaj.org/toc/2242-3982 2242-3982 doi:10.1080/22423982.2020.1758501 https://doaj.org/article/16425fe448d14bd6920642445f46808f International Journal of Circumpolar Health, Vol 79, Iss 1 (2020) inuit tuberculosis latent tuberculosis infection treatment Arctic medicine. Tropical medicine RC955-962 article 2020 ftdoajarticles https://doi.org/10.1080/22423982.2020.1758501 2022-12-31T16:29:55Z Background: The incidence of TB among Inuit is the highest in Canada. A significantly shorter latent TB infection (LTBI) treatment with rifapentine and isoniazid once weekly for 12 weeks (3HP) is now available in limited settings in Canada. Methods: A prospective open-label 2-year observational postmarketing study was conducted introducing 3HP for the first time in Canada in Iqaluit followed by a program rollout in Qikiqtarjuaq, Nunavut. Results: A total of 247 people were offered 3HP, 102 in the Iqaluit postmarketing study and 145 in the Qikiqtarjuaq program roll out. Although statistical significance was not reached, more people who started treatment completed treatment in the 3HP group (Iqaluit, 60/73 (82.2%) and Qikiqtarjuaq, 89/115 (77.4%)) than in the historical control 9INHgroup (306/420 = 72.9%) (p = 0.2). Most of the adverse events in 3HP treated patients were associated with mild discomfort but no disruption of normal daily activity. Not drinking alcohol was associated with increased 3HP completion (OR 13.33, 95% CI, 2.27–78.20) as was not taking concomitant medications (OR 7.19, 95% CI, 1.47–35.30). Conclusions: The present study supports the feasibility and safety profile of 3HP for the treatment of LTBI in Nunavut. Article in Journal/Newspaper Arctic Circumpolar Health International Journal of Circumpolar Health inuit Iqaluit Nunavut Qikiqtarjuaq Directory of Open Access Journals: DOAJ Articles Arctic Nunavut Canada Qikiqtarjuaq ENVELOPE(-64.029,-64.029,67.557,67.557) International Journal of Circumpolar Health 79 1 1758501 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
inuit tuberculosis latent tuberculosis infection treatment Arctic medicine. Tropical medicine RC955-962 |
spellingShingle |
inuit tuberculosis latent tuberculosis infection treatment Arctic medicine. Tropical medicine RC955-962 G. G. Alvarez D. Van Dyk R. Mallick S. Lesperance P. Demaio S. Finn S. Edmunds Potvin M. Patterson C. Pease K. Amaratunga C. Hui D.W. Cameron S. Mulpuru S.D. Aaron F. Momoli A. Zwerling The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study |
topic_facet |
inuit tuberculosis latent tuberculosis infection treatment Arctic medicine. Tropical medicine RC955-962 |
description |
Background: The incidence of TB among Inuit is the highest in Canada. A significantly shorter latent TB infection (LTBI) treatment with rifapentine and isoniazid once weekly for 12 weeks (3HP) is now available in limited settings in Canada. Methods: A prospective open-label 2-year observational postmarketing study was conducted introducing 3HP for the first time in Canada in Iqaluit followed by a program rollout in Qikiqtarjuaq, Nunavut. Results: A total of 247 people were offered 3HP, 102 in the Iqaluit postmarketing study and 145 in the Qikiqtarjuaq program roll out. Although statistical significance was not reached, more people who started treatment completed treatment in the 3HP group (Iqaluit, 60/73 (82.2%) and Qikiqtarjuaq, 89/115 (77.4%)) than in the historical control 9INHgroup (306/420 = 72.9%) (p = 0.2). Most of the adverse events in 3HP treated patients were associated with mild discomfort but no disruption of normal daily activity. Not drinking alcohol was associated with increased 3HP completion (OR 13.33, 95% CI, 2.27–78.20) as was not taking concomitant medications (OR 7.19, 95% CI, 1.47–35.30). Conclusions: The present study supports the feasibility and safety profile of 3HP for the treatment of LTBI in Nunavut. |
format |
Article in Journal/Newspaper |
author |
G. G. Alvarez D. Van Dyk R. Mallick S. Lesperance P. Demaio S. Finn S. Edmunds Potvin M. Patterson C. Pease K. Amaratunga C. Hui D.W. Cameron S. Mulpuru S.D. Aaron F. Momoli A. Zwerling |
author_facet |
G. G. Alvarez D. Van Dyk R. Mallick S. Lesperance P. Demaio S. Finn S. Edmunds Potvin M. Patterson C. Pease K. Amaratunga C. Hui D.W. Cameron S. Mulpuru S.D. Aaron F. Momoli A. Zwerling |
author_sort |
G. G. Alvarez |
title |
The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study |
title_short |
The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study |
title_full |
The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study |
title_fullStr |
The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study |
title_full_unstemmed |
The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study |
title_sort |
implementation of rifapentine and isoniazid (3hp) in two remote arctic communities with a predominantly inuit population, the taima tb 3hp study |
publisher |
Taylor & Francis Group |
publishDate |
2020 |
url |
https://doi.org/10.1080/22423982.2020.1758501 https://doaj.org/article/16425fe448d14bd6920642445f46808f |
long_lat |
ENVELOPE(-64.029,-64.029,67.557,67.557) |
geographic |
Arctic Nunavut Canada Qikiqtarjuaq |
geographic_facet |
Arctic Nunavut Canada Qikiqtarjuaq |
genre |
Arctic Circumpolar Health International Journal of Circumpolar Health inuit Iqaluit Nunavut Qikiqtarjuaq |
genre_facet |
Arctic Circumpolar Health International Journal of Circumpolar Health inuit Iqaluit Nunavut Qikiqtarjuaq |
op_source |
International Journal of Circumpolar Health, Vol 79, Iss 1 (2020) |
op_relation |
http://dx.doi.org/10.1080/22423982.2020.1758501 https://doaj.org/toc/2242-3982 2242-3982 doi:10.1080/22423982.2020.1758501 https://doaj.org/article/16425fe448d14bd6920642445f46808f |
op_doi |
https://doi.org/10.1080/22423982.2020.1758501 |
container_title |
International Journal of Circumpolar Health |
container_volume |
79 |
container_issue |
1 |
container_start_page |
1758501 |
_version_ |
1766330001985110016 |